The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 2,292,311 965.31 2,212,791,401
26 October 2026 11,106 1,043.19 11,585,670
27 October 2026 11,275 1,059.45 11,945,266
28 October 2026 11,081 1,077.84 11,943,566
29 October 2026 10,953 1,093.19 11,973,680
30 October 2026 10,835 1,080.93 11,711,853
Accumulated under the programme 2,347,561 967.79 2,271,951,437

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,347,561 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 4.03% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.

Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42.

Attachment

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 2,292,311 965.31 2,212,791,401
26 October 2026 11,106 1,043.19 11,585,670
27 October 2026 11,275 1,059.45 11,945,266
28 October 2026 11,081 1,077.84 11,943,566
29 October 2026 10,953 1,093.19 11,973,680
30 October 2026 10,835 1,080.93 11,711,853
Accumulated under the programme 2,347,561 967.79 2,271,951,437

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,347,561 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 4.03% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.

Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42.

Attachment

  • ACLF – Advancing a multi-target therapeutic strategy
    • GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of nangibotide into Phase 2 in this indication
    • Three poster presentations will provide new insights into the role of inflammation and immune dysregulation in acute liver failure, as well as further clinically relevant evidence of nitazoxanide’s anti-inflammatory activity, supporting its development in ACLF
    • Management to present at dedicated scientific meeting with NACSELD, a leading North American research consortium in cirrhosis and ACLF, to deepen scientific engagement
  • MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands
    • Taking a leading role in the Global Liver Institute’s Beyond the Biopsy – National Implementation Forum, bringing together drug manufacturers such as Novo Nordisk, Eli Lilly and Madrigal as well as KOLs to drive ecosystem-wide action on earlier patient identification and improved awareness of when, why and how to diagnose and monitor MASH
    • GENFIT’s expert panel on November 6, 2026, will highlight the importance of non-invasive testing in MASH for early detection of patients with active fibrotic MASH and monitoring of treatment response, as well as the unique potential of NIS™ Technology through converging perspectives from hepatology, diabetology, endocrinology, the pharmaceutical industry, and patients

Lille (France), Cambridge (Massachusetts, United States), November 2, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced a broad program of scientific and strategic activities taking place at the AASLD The Liver Meeting® 2026, highlighting progress across its therapeutic programs in Acute on-Chronic Liver Failure (ACLF) and diagnostics activities in Metabolic dysfunction-associated steatohepatitis (MASH).

ACLF – Advancing a multi-target therapeutic strategy

Scientific Event – November 8, 2026 |Advancing Clinical Development in ACLF
Building on Extensive Clinical Evidence and Research
The event will feature Professor Jennifer Lai (UC San Francisco) as a guest speaker, and will outline GENFIT’s multi-target approach to ACLF, aimed at addressing the complex pathophysiology of the disease through complementary therapeutic mechanisms. It will also provide an in-depth review of nangibotide, GENFIT’s TREM-1 modulator combining a strong biological rationale including safety data and promising efficacy signals across multiple organ systems from previous clinical studies in different indications. The development package for nangibotide includes an existing body of clinical evidence at the proposed dose, as well as available clinical supply and regulatory data informing GENFIT’s decision to advance into Phase 2 in ACLF.

Scientific posters to be presented – November 6, 2026 | 1:00–2:00 p.m. MT

  • Poster #2284: RIPK1 inhibition attenuates NET release and hemorrhagic liver injury in D-Galactosamine/LPS mice
  • Poster #2273: D-Galactosamine/LPS Acute Liver Failure Recapitulates Emergency Granulopoiesis-like Signatures Across the Bone Marrow–Spleen–Liver Axis
  • Poster #2034: Ex vivo blood assays demonstrate systemic anti-inflammatory activity of G1090N, a novel formulation of nitazoxanide, and support further clinical evaluation in acute-on-chronic liver failure (ACLF)

ACLF is characterized by high systemic inflammation and profound immune dysregulation. By bridging systemic immune dysregulation and pharmacological intervention, posters #2284 and #2273 presented at The Liver Meeting® will provide new insights into the role of the immune system, particularly neutrophils, in acute liver failure conditions. In addition, poster #2034 will provide further evidence of nitazoxanide’s anti-inflammatory activity, using blood samples collected in a clinical setting, supporting its clinical development in ACLF.

NACSELD Meeting – November 5, 2026
The North American Consortium for the Study of End-Stage Liver Disease (NACSELD), a leading multicenter research consortium focused on improving outcomes in cirrhosis and ACLF, will host a dedicated scientific meeting to provide an opportunity to discuss the evolving understanding of ACLF, key unmet needs and priorities for future therapeutic development, deepening scientific engagement. Building on GENFIT’s established partnership with NACSELD, management will present its ACLF strategy at this meeting chaired by Professor Jasmohan S. Bajaj, MD, MS, FAASLD, of Virginia Commonwealth University.

MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands

“Beyond the Biopsy” National Implementation Forum – November 4, 2026 | Global Liver Institute’s Initiative
The Global Liver Institute’s “Beyond the Biopsy “ National Implementation Forum will bring together clinical experts, patients, and diagnostics and pharmaceutical companies to address the practical barriers to implementing non-invasive MASH diagnostics at scale. Building on patient experiences and insights about LITMUS and NIMBLE, discussions moderated by Professor Brent A. Tetri, MD, will examine how to translate diagnostic innovation into real-world implementation across clinical pathways, access, reimbursement and policy. This involvement further strengthens GENFIT’s ties with Eli Lilly, Novo Nordisk, Madrigal and other leading pharmaceutical companies at the forefront of bringing new treatment options to tens of millions of patients in need. Larry Holden, CEO of the Global Liver Institute commented: “We are reaching an important inflection point in MASH: effective treatments are becoming available, making the ability to identify the right patients, particularly those with at-risk MASH, increasingly critical. Bringing together diagnostic innovators such as GENFIT, leading drug companies including Eli Lilly, Novo Nordisk and Madrigal, clinical experts from hepatology to endocrinology, patients and payers around the same table is exactly the type of dialogue needed to move from scientific progress to real-world implementation. As a pioneer in non-invasive MASH diagnostics, GENFIT has helped shape the field and continues to drive its evolution, with a clear vision of a future where therapeutic advances go hand in hand with effective patient identification and disease monitoring.”

Expert Panel – November 6, 2026 | Non-Invasive Diagnostics for At-Risk MASH
NISTM Technology Reshaping Patient Identification and Access to Care1
Professor Vlad Ratziu, MD, PhD (Sorbonne University, Pitié-Salpêtrière Hospital, IHU ICAN) and Professor Kenneth Cusi, MD, FACP, FACE (University of Florida, Division of Endocrinology, Diabetes & Metabolism) will share complementary hepatology and metabolic disease perspectives, while Wayne Eskridge and Henry Chang from the Fatty Liver Foundation will highlight how a simple and reliable blood-based technology could transform the patient journey and improve patient outcomes. Ashley Hamilton Chasick (Global Lead, Diagnostics Partnerships, Novo Nordisk), will complement these perspectives with an industry view on the importance of adopting non-invasive diagnostics in clinical practice to support earlier identification and monitoring of patients with at-risk MASH. The discussion will address current challenges in identifying and managing patients with at-risk MASH, a population characterized not only by fibrosis, but also by disease activity. It will highlight the growing role of non-invasive diagnostics as treatment uptake expands, and the potential contribution of GENFIT’s NIS™ Technology. Independent consortia in the US and Europe have validated GENFIT’s technology: NIMBLE identified it as the only one, among those evaluated, specifically intended to diagnose at-risk MASH, while LITMUS showed that it achieved the highest diagnostic accuracy among the blood-based, imaging and combined modalities evaluated for at-risk MASH. At-risk MASH is consistent with the population enrolled in the pivotal Phase 3 trials that supported the approval of currently approved MASH therapies.

GENFIT’s partner Ipsen is also expected to communicate on elafibranor during The Liver Meeting® 2026.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.2 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, the potential role, clinical utility and adoption of non-invasive MASH diagnostics, including GENFIT’s NIS™ Technology, in patient identification, disease monitoring and access to care; the potential opportunities associated with increasing uptake of MASH treatments, as well as the Company’s strategic plans and objectives. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the the Company’s ability to advance its therapeutic programs and initiate and complete clinical trials; uncertainties relating to regulatory requirements and decisions, patient enrollment, clinical trial execution, safety findings, manufacturing and clinical supply; the possibility that findings from prior studies in other indications, preclinical research or ex vivo assays may not predict safety, efficacy or clinical benefit in patients with ACLF; uncertainties relating to the clinical utility, further validation, adoption and use of non-invasive MASH diagnostics, including for disease or treatment- response monitoring; changes in clinical practice, treatment uptake, reimbursement, access and applicable regulatory requirements; and the Company’s dependence on partners and other third parties whose plans and activities may change. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company including the Half-Year 2026 Business and Financial Report. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. 

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com 


1 NIS™ Technology refers to NIS4® and its next-generation version, NIS2+® | NASHnext® (based on NIS4 technology) reimbursement by Medicare under the Clinical Laboratory Fee Schedule to Medicare patients that meet coverage criteria became effective on August 10, 2026 | NIS2+® is currently available through Labcorp in the United States as a Laboratory Developed Test (LDT). It has not been cleared or approved by the U.S. Food,and Drug Administration (FDA) and is not CE marked in the European Union
2 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

  • ACLF – Advancing a multi-target therapeutic strategy
    • GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of nangibotide into Phase 2 in this indication
    • Three poster presentations will provide new insights into the role of inflammation and immune dysregulation in acute liver failure, as well as further clinically relevant evidence of nitazoxanide’s anti-inflammatory activity, supporting its development in ACLF
    • Management to present at dedicated scientific meeting with NACSELD, a leading North American research consortium in cirrhosis and ACLF, to deepen scientific engagement
  • MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands
    • Taking a leading role in the Global Liver Institute’s Beyond the Biopsy – National Implementation Forum, bringing together drug manufacturers such as Novo Nordisk, Eli Lilly and Madrigal as well as KOLs to drive ecosystem-wide action on earlier patient identification and improved awareness of when, why and how to diagnose and monitor MASH
    • GENFIT’s expert panel on November 6, 2026, will highlight the importance of non-invasive testing in MASH for early detection of patients with active fibrotic MASH and monitoring of treatment response, as well as the unique potential of NIS™ Technology through converging perspectives from hepatology, diabetology, endocrinology, the pharmaceutical industry, and patients

Lille (France), Cambridge (Massachusetts, United States), November 2, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced a broad program of scientific and strategic activities taking place at the AASLD The Liver Meeting® 2026, highlighting progress across its therapeutic programs in Acute on-Chronic Liver Failure (ACLF) and diagnostics activities in Metabolic dysfunction-associated steatohepatitis (MASH).

ACLF – Advancing a multi-target therapeutic strategy

Scientific Event – November 8, 2026 |Advancing Clinical Development in ACLF
Building on Extensive Clinical Evidence and Research
The event will feature Professor Jennifer Lai (UC San Francisco) as a guest speaker, and will outline GENFIT’s multi-target approach to ACLF, aimed at addressing the complex pathophysiology of the disease through complementary therapeutic mechanisms. It will also provide an in-depth review of nangibotide, GENFIT’s TREM-1 modulator combining a strong biological rationale including safety data and promising efficacy signals across multiple organ systems from previous clinical studies in different indications. The development package for nangibotide includes an existing body of clinical evidence at the proposed dose, as well as available clinical supply and regulatory data informing GENFIT’s decision to advance into Phase 2 in ACLF.

Scientific posters to be presented – November 6, 2026 | 1:00–2:00 p.m. MT

  • Poster #2284: RIPK1 inhibition attenuates NET release and hemorrhagic liver injury in D-Galactosamine/LPS mice
  • Poster #2273: D-Galactosamine/LPS Acute Liver Failure Recapitulates Emergency Granulopoiesis-like Signatures Across the Bone Marrow–Spleen–Liver Axis
  • Poster #2034: Ex vivo blood assays demonstrate systemic anti-inflammatory activity of G1090N, a novel formulation of nitazoxanide, and support further clinical evaluation in acute-on-chronic liver failure (ACLF)

ACLF is characterized by high systemic inflammation and profound immune dysregulation. By bridging systemic immune dysregulation and pharmacological intervention, posters #2284 and #2273 presented at The Liver Meeting® will provide new insights into the role of the immune system, particularly neutrophils, in acute liver failure conditions. In addition, poster #2034 will provide further evidence of nitazoxanide’s anti-inflammatory activity, using blood samples collected in a clinical setting, supporting its clinical development in ACLF.

NACSELD Meeting – November 5, 2026
The North American Consortium for the Study of End-Stage Liver Disease (NACSELD), a leading multicenter research consortium focused on improving outcomes in cirrhosis and ACLF, will host a dedicated scientific meeting to provide an opportunity to discuss the evolving understanding of ACLF, key unmet needs and priorities for future therapeutic development, deepening scientific engagement. Building on GENFIT’s established partnership with NACSELD, management will present its ACLF strategy at this meeting chaired by Professor Jasmohan S. Bajaj, MD, MS, FAASLD, of Virginia Commonwealth University.

MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands

“Beyond the Biopsy” National Implementation Forum – November 4, 2026 | Global Liver Institute’s Initiative
The Global Liver Institute’s “Beyond the Biopsy “ National Implementation Forum will bring together clinical experts, patients, and diagnostics and pharmaceutical companies to address the practical barriers to implementing non-invasive MASH diagnostics at scale. Building on patient experiences and insights about LITMUS and NIMBLE, discussions moderated by Professor Brent A. Tetri, MD, will examine how to translate diagnostic innovation into real-world implementation across clinical pathways, access, reimbursement and policy. This involvement further strengthens GENFIT’s ties with Eli Lilly, Novo Nordisk, Madrigal and other leading pharmaceutical companies at the forefront of bringing new treatment options to tens of millions of patients in need. Larry Holden, CEO of the Global Liver Institute commented: “We are reaching an important inflection point in MASH: effective treatments are becoming available, making the ability to identify the right patients, particularly those with at-risk MASH, increasingly critical. Bringing together diagnostic innovators such as GENFIT, leading drug companies including Eli Lilly, Novo Nordisk and Madrigal, clinical experts from hepatology to endocrinology, patients and payers around the same table is exactly the type of dialogue needed to move from scientific progress to real-world implementation. As a pioneer in non-invasive MASH diagnostics, GENFIT has helped shape the field and continues to drive its evolution, with a clear vision of a future where therapeutic advances go hand in hand with effective patient identification and disease monitoring.”

Expert Panel – November 6, 2026 | Non-Invasive Diagnostics for At-Risk MASH
NISTM Technology Reshaping Patient Identification and Access to Care1
Professor Vlad Ratziu, MD, PhD (Sorbonne University, Pitié-Salpêtrière Hospital, IHU ICAN) and Professor Kenneth Cusi, MD, FACP, FACE (University of Florida, Division of Endocrinology, Diabetes & Metabolism) will share complementary hepatology and metabolic disease perspectives, while Wayne Eskridge and Henry Chang from the Fatty Liver Foundation will highlight how a simple and reliable blood-based technology could transform the patient journey and improve patient outcomes. Ashley Hamilton Chasick (Global Lead, Diagnostics Partnerships, Novo Nordisk), will complement these perspectives with an industry view on the importance of adopting non-invasive diagnostics in clinical practice to support earlier identification and monitoring of patients with at-risk MASH. The discussion will address current challenges in identifying and managing patients with at-risk MASH, a population characterized not only by fibrosis, but also by disease activity. It will highlight the growing role of non-invasive diagnostics as treatment uptake expands, and the potential contribution of GENFIT’s NIS™ Technology. Independent consortia in the US and Europe have validated GENFIT’s technology: NIMBLE identified it as the only one, among those evaluated, specifically intended to diagnose at-risk MASH, while LITMUS showed that it achieved the highest diagnostic accuracy among the blood-based, imaging and combined modalities evaluated for at-risk MASH. At-risk MASH is consistent with the population enrolled in the pivotal Phase 3 trials that supported the approval of currently approved MASH therapies.

GENFIT’s partner Ipsen is also expected to communicate on elafibranor during The Liver Meeting® 2026.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.2 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, the potential role, clinical utility and adoption of non-invasive MASH diagnostics, including GENFIT’s NIS™ Technology, in patient identification, disease monitoring and access to care; the potential opportunities associated with increasing uptake of MASH treatments, as well as the Company’s strategic plans and objectives. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the the Company’s ability to advance its therapeutic programs and initiate and complete clinical trials; uncertainties relating to regulatory requirements and decisions, patient enrollment, clinical trial execution, safety findings, manufacturing and clinical supply; the possibility that findings from prior studies in other indications, preclinical research or ex vivo assays may not predict safety, efficacy or clinical benefit in patients with ACLF; uncertainties relating to the clinical utility, further validation, adoption and use of non-invasive MASH diagnostics, including for disease or treatment- response monitoring; changes in clinical practice, treatment uptake, reimbursement, access and applicable regulatory requirements; and the Company’s dependence on partners and other third parties whose plans and activities may change. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company including the Half-Year 2026 Business and Financial Report. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. 

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com 


1 NIS™ Technology refers to NIS4® and its next-generation version, NIS2+® | NASHnext® (based on NIS4 technology) reimbursement by Medicare under the Clinical Laboratory Fee Schedule to Medicare patients that meet coverage criteria became effective on August 10, 2026 | NIS2+® is currently available through Labcorp in the United States as a Laboratory Developed Test (LDT). It has not been cleared or approved by the U.S. Food,and Drug Administration (FDA) and is not CE marked in the European Union
2 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the supply of MVA-BN®, a non-replicating vaccine indicated for the prevention of mpox and smallpox, further supporting the UK’s long-term preparedness against emerging infectious disease threats.

Under the four-year contract, Bavarian Nordic will supply MVA-BN through scheduled deliveries across the term. The contract also includes optional flexibility provisions.

The award reinforces the longstanding partnership between Bavarian Nordic and the UK government and supports the UK’s commitment to maintaining vaccine preparedness and response capabilities against public health threats.

Sarah Collins, Director, Commercial, Vaccines & Countermeasures Delivery at UKHSA said: “It is vital to ensure that the UK has the right vaccines available to protect the public from a range of infectious disease threats. Working with a range of trusted suppliers helps us build a resilient and flexible vaccine supply chain, so we can respond quickly and effectively. This contract is an important part of that ongoing work to keep the public safe.”

“We are pleased to continue supporting the UK government’s preparedness efforts through this multi-year agreement,” said Hitesh Sahni, Senior Vice President, Public Preparedness at Bavarian Nordic. “Maintaining sustainable vaccine stockpiles and rapid response capabilities are essential to protecting public health and saving lives and we are proud that our vaccine remains an important component of the UK’s resilience strategy.”

The MVA-BN vaccine has been a key tool in outbreak preparedness and response efforts globally. Governments and public health authorities continue to recognize the importance of maintaining access to vaccines that can be deployed rapidly in response to evolving epidemiological situations.

The new contract follows previous vaccine procurements by the UK government aimed at strengthening national resilience and ensuring the availability of vaccine supplies for eligible populations and outbreak response activities.

About MVA-BN®
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore, Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), the EU/EEA European Economic Area and United Kingdom (marketed as IMVANEX®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 2 years old) in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Attachment

COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the supply of MVA-BN®, a non-replicating vaccine indicated for the prevention of mpox and smallpox, further supporting the UK’s long-term preparedness against emerging infectious disease threats.

Under the four-year contract, Bavarian Nordic will supply MVA-BN through scheduled deliveries across the term. The contract also includes optional flexibility provisions.

The award reinforces the longstanding partnership between Bavarian Nordic and the UK government and supports the UK’s commitment to maintaining vaccine preparedness and response capabilities against public health threats.

Sarah Collins, Director, Commercial, Vaccines & Countermeasures Delivery at UKHSA said: “It is vital to ensure that the UK has the right vaccines available to protect the public from a range of infectious disease threats. Working with a range of trusted suppliers helps us build a resilient and flexible vaccine supply chain, so we can respond quickly and effectively. This contract is an important part of that ongoing work to keep the public safe.”

“We are pleased to continue supporting the UK government’s preparedness efforts through this multi-year agreement,” said Hitesh Sahni, Senior Vice President, Public Preparedness at Bavarian Nordic. “Maintaining sustainable vaccine stockpiles and rapid response capabilities are essential to protecting public health and saving lives and we are proud that our vaccine remains an important component of the UK’s resilience strategy.”

The MVA-BN vaccine has been a key tool in outbreak preparedness and response efforts globally. Governments and public health authorities continue to recognize the importance of maintaining access to vaccines that can be deployed rapidly in response to evolving epidemiological situations.

The new contract follows previous vaccine procurements by the UK government aimed at strengthening national resilience and ensuring the availability of vaccine supplies for eligible populations and outbreak response activities.

About MVA-BN®
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore, Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), the EU/EEA European Economic Area and United Kingdom (marketed as IMVANEX®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 2 years old) in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Attachment

  • H1 2026/27 performance impacted by execution issues
    • Order intake1 of €11.0 billion, book-to-bill ratio1 of 1.2, consistent with full-year guidance
    • Operational and financial performance mainly impacted by Coradia Max platform
      • Industrialisation challenges and extended homologation timeline for Coradia Max
      • Other projects executed for, and from, Germany also impacted
    • Car production of 1,860, trending below planned trajectory
    • Group sales of €9.3 billion, up 3%, including 2% organic growth1
    • Adjusted EBIT margin1 of around (4)%, impacted by execution issues
    • Free Cash Flow1 of €(1,248) million, reflecting seasonality
  • FY 2026/27 guidance adjusted:
    • Group book-to-bill ratio1 above 1 (unchanged)
    • Low- to mid-single digit organic sales growth1 (vs around 5% previously)
    • Car production around 4,000 (vs 4,400-4,500 previously)
    • Adjusted EBIT margin1 of around 1% (vs around 6.5% previously), implying around 6.5% in H2 2026/27
    • Free Cash Flow1 of €(1.5) billion euro (vs ‘Positive’ previously)
  • Placing project execution excellence as the Group’s top priority
    • Priority initiatives launched since April 2026: leaner operations, faster issue resolution, enhanced accountability, stronger cost and procurement discipline, and simpler processes.
    • On-going broad review of the organisational and operational models, leading to decisions to be made by early 2027.
    • Capital Markets Day in the second quarter of 2027 to encompass organisational model, operations, footprint and product offering together with medium-term financial trajectory.
  • Deleveraging objective of around €2 billion.

2 November 2026 – The Board of Directors of Alstom met on 1 November 2026 and reviewed the preliminary unaudited results for the first half of fiscal year 2026/27. Martin Sion, CEO of Alstom, said:

“Since my appointment as CEO in April 2026, I have requested rigorous identification and escalation of project-level risks and opportunities, mobilising dedicated teams of Alstom experts on most critical projects, including Coradia Max. Today’s announcement reflects the consequences of this exercise with the objective to normalise the Group’s performance from next fiscal year. It also reinforces my determination to accelerate operational improvements and calls for a deleveraging plan, with the support of our Board, to ensure Alstom realises the full potential of its competitive positioning on the growing rail market”

Key figures

  Half year ended 30 September 2025 Half year ended 30 September 2026 % Change Reported % Change Organic2
Orders received2 (€ billion) 10.5 11.0 5% 5%
Sales (€ billion) 9.1 9.3 3% 2%
Adjusted EBIT margin2 6.4% ~(4)%    
Free Cash Flow2 (€ million) (740) (1,248)    

Preliminary H1 2026/27 review

Orders

In the first half of fiscal year 2026/27, Alstom recorded orders of €11.0 billion, compared with €10.5 billion in the same period of the previous fiscal year. Commercial momentum accelerated in the second quarter, with orders of €8.4 billion and a book-to-bill ratio of 1.8. The first-half book-to-bill ratio was therefore 1.2, consistent with the full-year guidance of above 1.

Sales

Sales reached €9.3 billion in the first half of fiscal year 2026/27, up 3% on a reported basis and 2% on an organic basis compared to the same period last fiscal year.

Alstom manufactured 1,860 cars during the first half, down 8% compared with 2,017 in the same period of the previous fiscal year. Production was affected by execution issues on the Coradia Max platform, with manufacturing paused during the first quarter to resolve identified issues and minimise subsequent retrofit work.

Profitability

Adjusted EBIT margin for the first half of fiscal year 2026/27 stands at around (4)%, compared with 6.4% in the first half of the previous fiscal year. The decline compared to the same period last fiscal year was largely attributable to gross margin adjustments on projects executed for, and from, Germany.

In the first half of fiscal year 2026/27, additional technical issues and testing requirements related to the Coradia Max platform surfaced. In parallel, strengthened reviews of some of the most critical Rolling Stock projects provided enhanced visibility on execution risks, additional work required, project timelines and knock-on effects on other projects.

These developments led to revised margins at completion on selected projects.

Free Cash Flow

The Group’s Free Cash Flow stands at €(1,248) million in the first half of fiscal year 2026/27, reflecting seasonality. Free-Cash-Flow consumption compared to first-half guidance was partly mitigated by a few milestone payments and downpayments being brought forward into the first half of fiscal year 2026/27.

Net debt

As of 30 September 2026, the Group reported net debt of €1.1 billion, compared with €0.4 billion as of 31 March 2026. The increase primarily reflects Free Cash Flow consumption of €(1,248) million, a €44 million coupon payment on subordinated perpetual securities, and an €81 million increase in lease liabilities. These effects were partly offset by €694 million of proceeds from the issuance of a green hybrid bond in June 2026.

FY 2026/27 outlook

Following preliminary results for the first half of fiscal year 2026/27, the Group is adjusting its outlook for the fiscal year 2026/27 as follows:

  • Book-to-bill ratio of above 1 for fiscal year 2026/27, unchanged from previous outlook, supported by continued demand, a solid pipeline of opportunities, and ongoing operational and deleveraging initiatives.
  • Car production of around 4,000 in fiscal year 2026/27, compared with 4,400–4,500 previously, partly reflecting the production shortfall recorded in the first half versus planned trajectory.
  • Organic sales growth of low- to mid-single digit in fiscal year 2026/27, compared to around 5% previously, partly impacted by lower car production than initially expected.
  • Adjusted EBIT margin of around 1% for fiscal year 2026/27, down from 6.5% as announced previously, implying a rebound in adjusted EBIT margin of around 6.5% in the second half fiscal year 2026/27.
  • Free Cash Flow of €(1.5) billion in fiscal year 2026/27, compared with ‘Positive’ Free Cash Flow previously, predominantly driven by milestone payments shifting into subsequent fiscal years as a result of extended homologation timelines and later-than-anticipated entry into commercial service of major projects, including Coradia Max, as well as certain commercial opportunities.

The project-level identification and escalation of risks and opportunities, initiated by dedicated Alstom expert teams, is expected to be completed by fiscal-year end. As a result, the Group expects performance to normalise from fiscal 2027/28 onwards and trend towards 8-10% adjusted EBIT over the medium term.

Reinforce Balance Sheet to maintain Investment Grade rating

Conservative liquidity policy

In addition to its available cash and cash equivalents, amounting to €1.65 billion as of 30 September 2026, the Group benefits from the following liquidity lines:

  • €2.5 billion short term Revolving Credit Facility maturing in July 2029
  • €1.75 billion Backstop Revolving Credit Facility maturing in January 2029 serving as back-up to the Group’s €2.5 billion NEU Commercial Paper programme

As of 30 September 2026, the short-term Revolving Credit Facility was fully undrawn and the outstanding balance under the NEU Commercial Paper programme was nil.

On 1 November 2026, the Group entered a new €2.0 billion short term Revolving Credit Facility with a first-tier international bank, further strengthening its financial flexibility. The facility is not subject to financial covenants and matures in November 2028.

Placing project execution excellence as the Group’s top priority

Based on lessons learnt from Coradia Max and other projects, Alstom is developing a comprehensive action plan to address the root causes identified. As a first step, the Group has maintained dedicated teams of Alstom experts to identify risks and opportunities and enhance remediation plans at project level.

The Group’s near-term priorities are centred on consistent deployment of lean practices in manufacturing and engineering, faster resolution of operational issues, greater accountability of project managers, cost and procurement initiatives and simplification of processes. The Group is also reviewing the organisational and operational models, with key decisions expected by early 2027.

Finally, Alstom is pursuing a broad operational plan designed to support sustainable performance over the longer term, with the objective of better aligning its operating model, operations, industrial footprint and product and services offering.

Deleveraging objective

Alstom’s Board of Directors is committed to maintaining a solid investment-grade credit rating. It has therefore decided to initiate a review of all possible organic and inorganic options in order to achieve a debt reduction of around €2 billion by September 2027.

The board-represented shareholders are supportive of the Group and are closely working with the management to carry out such review.

The Group will retain flexibility over the sequencing and sizing of the selected measures.

Capital Markets Day in the second quarter of 2027

In parallel with the execution of the deleveraging plan, the Group will unveil its long-term strategic and operational plan and medium-term outlook at a Capital Markets Day to be held in the second quarter of calendar year 2027.

Financial Calendar

17 November 2026 FY 2026/27 Half-Year Results
19 January 2027 FY 2026/27 Third Quarter – Orders & Sales

Conference Call

Alstom invites the analysts to a conference call presenting preliminary figures for the first half of fiscal year 2026/27 on Monday 2 November at 8:00 am (Paris local time), hosted by Martin Sion, CEO, and Bernard Delpit, EVP and CFO.

A live audiocast will also be available on Alstom’s website: Alstom’s preliminary Half Year results for FY 2026/27

To participate in the Q&A session (audio only), please register here.

You will then receive all necessary information by e-mail. We strongly advise connecting at least 10 minutes in advance.

ALSTOM™, Coradia™ and Coradia Max™ are protected trademarks of the Alstom Group.

About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transport. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 87,800 people in 61 countries, Alstom brings together global expertise and local know-how to make every journey smarter, cleaner and more enjoyable. Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €19.2 billion for the fiscal year ending 31 March 2026.
For more information, please visit www.alstom.com
Contacts Press:
HQ
Charles-Etienne LEBATARD – T: +33 (0) 7 63 43 68 60
mediarelations@alstomgroup.com

Philippe MOLITOR – T +33 (0) 7 76 00 97 79
Philippe.molitor@alstomgroup.com

Investor Relations:
Cyril GUÉRIN – T: +33 (0) 6 07 89 36 16
cyril.guerin@alstomgroup.com

Guillaume GAUVILLÉ – T: +44 (0) 7 588 022 744
guillaume.gauville@alstomgroup.com

Jalal DAHMANE – T: +33 (0) 6 98 19 96 62
jalal.dahmane@alstomgroup.com

This press release contains forward-looking statements which are based on current plans and forecasts of Alstom’s management. Such forward-looking statements are relevant to the current scope of activity and are by their nature subject to a number of important risks and uncertainty factors (such as those described in the documents filed by Alstom with the French AMF) that could cause reported results to differ from the plans, objectives and expectations expressed in such forward-looking statements. Such forward-looking statements speak only as of the date on which they are made, and Alstom undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise. This press release does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, the United Kingdom, the United States or any other jurisdiction. Any offer of the Company’s securities may only be made in France pursuant to a prospectus having received the approval from the AMF or, outside France, pursuant to an offering document prepared for such purpose. The information does not constitute any form of commitment on the part of the Company or any other person. Neither the information nor any other written or oral information made available to any recipient, or its advisers will form the basis of any contract or commitment whatsoever. In particular, in furnishing the information, the Company, the Joint Global Coordinators, their affiliates, shareholders, and their respective directors, officers, advisers, employees or representatives undertake no obligation to provide the recipient with access to any additional information.
Appendix 1 – Non-GAAP Financial Indicators Definitions

This section presents financial indicators used by the Group that are not defined by accounting standard setters.

Orders received

A new order is recognised as an order received only when the contract creates enforceable obligations between the Group and its customer.

When this condition is met, the order is recognised at the contract value.

If the contract is denominated in a currency other than the functional currency of the reporting unit, the Group requires the immediate elimination of currency exposure using forward currency sales. Orders are then measured using the spot rate at inception of hedging instruments.

Book-to-Bill

The book-to-bill ratio is the ratio of orders received to the amount of sales traded for a specific period.

Gross margin % on backlog

Gross Margin % on backlog is a KPI that presents the expected performance level of firm contracts in backlog. It represents the difference between the sales not yet recognized and the cost of sales not yet incurred from the contracts in backlog. This % is an average of the portfolio of contracts in backlog and is meaningful to project mid- and long-term profitability.

Adjusted Gross Margin before PPA

Adjusted Gross Margin before PPA is a KPI that presents the level of recurring operational performance. It represents the sales minus the cost of sales, adjusted to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination as well as significant, non-recurring “one off” items that are not expected to occur again in subsequent years.

EBIT before PPA

Following the Bombardier Transportation acquisition and with effect from the fiscal year 2021/22 condensed consolidated financial statements, Alstom decided to introduce the “EBIT before PPA” KPI aimed at restating its Earnings Before Interest and Taxes (“EBIT”) to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination. This KPI is also aligned with market practice.

Adjusted EBIT

Adjusted EBIT (“aEBIT”) is a KPI that presents the level of recurring operational performance. This KPI is also aligned with market practice and comparable to the Group’s direct competitors.

Since September 2019, Alstom has opted for the inclusion of the share in net income of the equity-accounted investments into the aEBIT even though this component is part of the operating activities of the Group (because there are significant operational flows and/or common project execution associated with these entities). This mainly includes Chinese joint ventures, namely CASCO joint venture for Alstom as well as, following the integration of Bombardier Transportation, Alstom Sifang (Qingdao) Transportation Ltd., Jiangsu Alstom NUG Propulsion System Co. Ltd.

aEBIT corresponds to Earning Before Interests and Tax adjusted for the following elements:

  • Net restructuring expenses (including rationalisation costs);
  • Tangibles and intangibles impairment;
  • Capital gains or loss/revaluation on investments disposals or controls changes of an entity;
  • Any other non-recurring items, such as some costs incurred to realise business combinations and amortisation of an asset exclusively valued in the context of business combination, as well as litigation costs that have arisen outside the ordinary course of business;
  • And including the share in net income of the operational equity-accounted investments.

A non-recurring item is a significant, “one-off” exceptional item that is not expected to occur again in subsequent years.

Adjusted EBIT margin corresponds to Adjusted EBIT expressed as a percentage of sales.

EBITDA before PPA + JV dividends

EBITDA before PPA plus dividends from joint ventures is the EBIT before PPA, before depreciation and amortisation, with the addition of the dividends received from joint ventures.

Adjusted net profit

The “Adjusted Net Profit” KPI restates Alstom’s net profit from continued operations (Group share) to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination, net of the corresponding tax effect. This indicator is also aligned with market practice.

Free cash flow

Free Cash Flow is defined as net cash provided by operating activities less capital expenditures including capitalised development costs, net of proceeds from disposals of tangible and intangible assets. Free Cash Flow does not include any proceeds from disposals of activity.

The most directly comparable financial measure to Free Cash Flow calculated and presented in accordance with IFRS is net cash provided by operating activities.

Funds from Operations

Funds from Operations “FFO” in the EBIT before PPA to Free Cash Flow statement refers to the Free Cash Flow generated by Operations, before Working Capital variations.

Contract and Trade Working Capital

Contract Working Capital is the sum of:

  • Contract Assets & Liabilities, which includes the Customer Down-Payments
  • Current provisions, which includes Risks on contracts and Warranties

Trade Working Capital is the Working Capital that is not strictly contractual, hence not included in Project Working Capital. It includes:

  • Inventories
  • Trade Receivables
  • Trade Payables
  • Other elements of Working Capital defined as the sum of Other Current Assets/Liabilities and Non-Current provisions 

Net cash/(debt)

The net cash/(debt) is defined as cash and cash equivalents, marketable securities and other current financial asset, less borrowings.

Organic basis

This press release includes KPIs presented on an actual basis and on an organic basis. Figures given on an organic basis eliminate the impact of changes in scope of consolidation and changes resulting from the translation of the accounts into Euro following the variation of foreign currencies against the Euro.

The Group uses figures prepared on an organic basis both for internal analysis and for external communication, as it believes they provide means to analyse and explain variations from one period to another. However, these figures are not measurements of performance under IFRS.


1 Non-GAAP. See definition in the appendix

2 Non-GAAP. See definition in the appendix

Attachment

  • H1 2026/27 performance impacted by execution issues
    • Order intake1 of €11.0 billion, book-to-bill ratio1 of 1.2, consistent with full-year guidance
    • Operational and financial performance mainly impacted by Coradia Max platform
      • Industrialisation challenges and extended homologation timeline for Coradia Max
      • Other projects executed for, and from, Germany also impacted
    • Car production of 1,860, trending below planned trajectory
    • Group sales of €9.3 billion, up 3%, including 2% organic growth1
    • Adjusted EBIT margin1 of around (4)%, impacted by execution issues
    • Free Cash Flow1 of €(1,248) million, reflecting seasonality
  • FY 2026/27 guidance adjusted:
    • Group book-to-bill ratio1 above 1 (unchanged)
    • Low- to mid-single digit organic sales growth1 (vs around 5% previously)
    • Car production around 4,000 (vs 4,400-4,500 previously)
    • Adjusted EBIT margin1 of around 1% (vs around 6.5% previously), implying around 6.5% in H2 2026/27
    • Free Cash Flow1 of €(1.5) billion euro (vs ‘Positive’ previously)
  • Placing project execution excellence as the Group’s top priority
    • Priority initiatives launched since April 2026: leaner operations, faster issue resolution, enhanced accountability, stronger cost and procurement discipline, and simpler processes.
    • On-going broad review of the organisational and operational models, leading to decisions to be made by early 2027.
    • Capital Markets Day in the second quarter of 2027 to encompass organisational model, operations, footprint and product offering together with medium-term financial trajectory.
  • Deleveraging objective of around €2 billion.

2 November 2026 – The Board of Directors of Alstom met on 1 November 2026 and reviewed the preliminary unaudited results for the first half of fiscal year 2026/27. Martin Sion, CEO of Alstom, said:

“Since my appointment as CEO in April 2026, I have requested rigorous identification and escalation of project-level risks and opportunities, mobilising dedicated teams of Alstom experts on most critical projects, including Coradia Max. Today’s announcement reflects the consequences of this exercise with the objective to normalise the Group’s performance from next fiscal year. It also reinforces my determination to accelerate operational improvements and calls for a deleveraging plan, with the support of our Board, to ensure Alstom realises the full potential of its competitive positioning on the growing rail market”

Key figures

  Half year ended 30 September 2025 Half year ended 30 September 2026 % Change Reported % Change Organic2
Orders received2 (€ billion) 10.5 11.0 5% 5%
Sales (€ billion) 9.1 9.3 3% 2%
Adjusted EBIT margin2 6.4% ~(4)%    
Free Cash Flow2 (€ million) (740) (1,248)    

Preliminary H1 2026/27 review

Orders

In the first half of fiscal year 2026/27, Alstom recorded orders of €11.0 billion, compared with €10.5 billion in the same period of the previous fiscal year. Commercial momentum accelerated in the second quarter, with orders of €8.4 billion and a book-to-bill ratio of 1.8. The first-half book-to-bill ratio was therefore 1.2, consistent with the full-year guidance of above 1.

Sales

Sales reached €9.3 billion in the first half of fiscal year 2026/27, up 3% on a reported basis and 2% on an organic basis compared to the same period last fiscal year.

Alstom manufactured 1,860 cars during the first half, down 8% compared with 2,017 in the same period of the previous fiscal year. Production was affected by execution issues on the Coradia Max platform, with manufacturing paused during the first quarter to resolve identified issues and minimise subsequent retrofit work.

Profitability

Adjusted EBIT margin for the first half of fiscal year 2026/27 stands at around (4)%, compared with 6.4% in the first half of the previous fiscal year. The decline compared to the same period last fiscal year was largely attributable to gross margin adjustments on projects executed for, and from, Germany.

In the first half of fiscal year 2026/27, additional technical issues and testing requirements related to the Coradia Max platform surfaced. In parallel, strengthened reviews of some of the most critical Rolling Stock projects provided enhanced visibility on execution risks, additional work required, project timelines and knock-on effects on other projects.

These developments led to revised margins at completion on selected projects.

Free Cash Flow

The Group’s Free Cash Flow stands at €(1,248) million in the first half of fiscal year 2026/27, reflecting seasonality. Free-Cash-Flow consumption compared to first-half guidance was partly mitigated by a few milestone payments and downpayments being brought forward into the first half of fiscal year 2026/27.

Net debt

As of 30 September 2026, the Group reported net debt of €1.1 billion, compared with €0.4 billion as of 31 March 2026. The increase primarily reflects Free Cash Flow consumption of €(1,248) million, a €44 million coupon payment on subordinated perpetual securities, and an €81 million increase in lease liabilities. These effects were partly offset by €694 million of proceeds from the issuance of a green hybrid bond in June 2026.

FY 2026/27 outlook

Following preliminary results for the first half of fiscal year 2026/27, the Group is adjusting its outlook for the fiscal year 2026/27 as follows:

  • Book-to-bill ratio of above 1 for fiscal year 2026/27, unchanged from previous outlook, supported by continued demand, a solid pipeline of opportunities, and ongoing operational and deleveraging initiatives.
  • Car production of around 4,000 in fiscal year 2026/27, compared with 4,400–4,500 previously, partly reflecting the production shortfall recorded in the first half versus planned trajectory.
  • Organic sales growth of low- to mid-single digit in fiscal year 2026/27, compared to around 5% previously, partly impacted by lower car production than initially expected.
  • Adjusted EBIT margin of around 1% for fiscal year 2026/27, down from 6.5% as announced previously, implying a rebound in adjusted EBIT margin of around 6.5% in the second half fiscal year 2026/27.
  • Free Cash Flow of €(1.5) billion in fiscal year 2026/27, compared with ‘Positive’ Free Cash Flow previously, predominantly driven by milestone payments shifting into subsequent fiscal years as a result of extended homologation timelines and later-than-anticipated entry into commercial service of major projects, including Coradia Max, as well as certain commercial opportunities.

The project-level identification and escalation of risks and opportunities, initiated by dedicated Alstom expert teams, is expected to be completed by fiscal-year end. As a result, the Group expects performance to normalise from fiscal 2027/28 onwards and trend towards 8-10% adjusted EBIT over the medium term.

Reinforce Balance Sheet to maintain Investment Grade rating

Conservative liquidity policy

In addition to its available cash and cash equivalents, amounting to €1.65 billion as of 30 September 2026, the Group benefits from the following liquidity lines:

  • €2.5 billion short term Revolving Credit Facility maturing in July 2029
  • €1.75 billion Backstop Revolving Credit Facility maturing in January 2029 serving as back-up to the Group’s €2.5 billion NEU Commercial Paper programme

As of 30 September 2026, the short-term Revolving Credit Facility was fully undrawn and the outstanding balance under the NEU Commercial Paper programme was nil.

On 1 November 2026, the Group entered a new €2.0 billion short term Revolving Credit Facility with a first-tier international bank, further strengthening its financial flexibility. The facility is not subject to financial covenants and matures in November 2028.

Placing project execution excellence as the Group’s top priority

Based on lessons learnt from Coradia Max and other projects, Alstom is developing a comprehensive action plan to address the root causes identified. As a first step, the Group has maintained dedicated teams of Alstom experts to identify risks and opportunities and enhance remediation plans at project level.

The Group’s near-term priorities are centred on consistent deployment of lean practices in manufacturing and engineering, faster resolution of operational issues, greater accountability of project managers, cost and procurement initiatives and simplification of processes. The Group is also reviewing the organisational and operational models, with key decisions expected by early 2027.

Finally, Alstom is pursuing a broad operational plan designed to support sustainable performance over the longer term, with the objective of better aligning its operating model, operations, industrial footprint and product and services offering.

Deleveraging objective

Alstom’s Board of Directors is committed to maintaining a solid investment-grade credit rating. It has therefore decided to initiate a review of all possible organic and inorganic options in order to achieve a debt reduction of around €2 billion by September 2027.

The board-represented shareholders are supportive of the Group and are closely working with the management to carry out such review.

The Group will retain flexibility over the sequencing and sizing of the selected measures.

Capital Markets Day in the second quarter of 2027

In parallel with the execution of the deleveraging plan, the Group will unveil its long-term strategic and operational plan and medium-term outlook at a Capital Markets Day to be held in the second quarter of calendar year 2027.

Financial Calendar

17 November 2026 FY 2026/27 Half-Year Results
19 January 2027 FY 2026/27 Third Quarter – Orders & Sales

Conference Call

Alstom invites the analysts to a conference call presenting preliminary figures for the first half of fiscal year 2026/27 on Monday 2 November at 8:00 am (Paris local time), hosted by Martin Sion, CEO, and Bernard Delpit, EVP and CFO.

A live audiocast will also be available on Alstom’s website: Alstom’s preliminary Half Year results for FY 2026/27

To participate in the Q&A session (audio only), please register here.

You will then receive all necessary information by e-mail. We strongly advise connecting at least 10 minutes in advance.

ALSTOM™, Coradia™ and Coradia Max™ are protected trademarks of the Alstom Group.

About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transport. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions. With 87,800 people in 61 countries, Alstom brings together global expertise and local know-how to make every journey smarter, cleaner and more enjoyable. Together with our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €19.2 billion for the fiscal year ending 31 March 2026.
For more information, please visit www.alstom.com
Contacts Press:
HQ
Charles-Etienne LEBATARD – T: +33 (0) 7 63 43 68 60
mediarelations@alstomgroup.com

Philippe MOLITOR – T +33 (0) 7 76 00 97 79
Philippe.molitor@alstomgroup.com

Investor Relations:
Cyril GUÉRIN – T: +33 (0) 6 07 89 36 16
cyril.guerin@alstomgroup.com

Guillaume GAUVILLÉ – T: +44 (0) 7 588 022 744
guillaume.gauville@alstomgroup.com

Jalal DAHMANE – T: +33 (0) 6 98 19 96 62
jalal.dahmane@alstomgroup.com

This press release contains forward-looking statements which are based on current plans and forecasts of Alstom’s management. Such forward-looking statements are relevant to the current scope of activity and are by their nature subject to a number of important risks and uncertainty factors (such as those described in the documents filed by Alstom with the French AMF) that could cause reported results to differ from the plans, objectives and expectations expressed in such forward-looking statements. Such forward-looking statements speak only as of the date on which they are made, and Alstom undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise. This press release does not constitute or form part of a prospectus or any offer or invitation for the sale or issue of, or any offer or inducement to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any shares or other securities in the Company in France, the United Kingdom, the United States or any other jurisdiction. Any offer of the Company’s securities may only be made in France pursuant to a prospectus having received the approval from the AMF or, outside France, pursuant to an offering document prepared for such purpose. The information does not constitute any form of commitment on the part of the Company or any other person. Neither the information nor any other written or oral information made available to any recipient, or its advisers will form the basis of any contract or commitment whatsoever. In particular, in furnishing the information, the Company, the Joint Global Coordinators, their affiliates, shareholders, and their respective directors, officers, advisers, employees or representatives undertake no obligation to provide the recipient with access to any additional information.
Appendix 1 – Non-GAAP Financial Indicators Definitions

This section presents financial indicators used by the Group that are not defined by accounting standard setters.

Orders received

A new order is recognised as an order received only when the contract creates enforceable obligations between the Group and its customer.

When this condition is met, the order is recognised at the contract value.

If the contract is denominated in a currency other than the functional currency of the reporting unit, the Group requires the immediate elimination of currency exposure using forward currency sales. Orders are then measured using the spot rate at inception of hedging instruments.

Book-to-Bill

The book-to-bill ratio is the ratio of orders received to the amount of sales traded for a specific period.

Gross margin % on backlog

Gross Margin % on backlog is a KPI that presents the expected performance level of firm contracts in backlog. It represents the difference between the sales not yet recognized and the cost of sales not yet incurred from the contracts in backlog. This % is an average of the portfolio of contracts in backlog and is meaningful to project mid- and long-term profitability.

Adjusted Gross Margin before PPA

Adjusted Gross Margin before PPA is a KPI that presents the level of recurring operational performance. It represents the sales minus the cost of sales, adjusted to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination as well as significant, non-recurring “one off” items that are not expected to occur again in subsequent years.

EBIT before PPA

Following the Bombardier Transportation acquisition and with effect from the fiscal year 2021/22 condensed consolidated financial statements, Alstom decided to introduce the “EBIT before PPA” KPI aimed at restating its Earnings Before Interest and Taxes (“EBIT”) to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination. This KPI is also aligned with market practice.

Adjusted EBIT

Adjusted EBIT (“aEBIT”) is a KPI that presents the level of recurring operational performance. This KPI is also aligned with market practice and comparable to the Group’s direct competitors.

Since September 2019, Alstom has opted for the inclusion of the share in net income of the equity-accounted investments into the aEBIT even though this component is part of the operating activities of the Group (because there are significant operational flows and/or common project execution associated with these entities). This mainly includes Chinese joint ventures, namely CASCO joint venture for Alstom as well as, following the integration of Bombardier Transportation, Alstom Sifang (Qingdao) Transportation Ltd., Jiangsu Alstom NUG Propulsion System Co. Ltd.

aEBIT corresponds to Earning Before Interests and Tax adjusted for the following elements:

  • Net restructuring expenses (including rationalisation costs);
  • Tangibles and intangibles impairment;
  • Capital gains or loss/revaluation on investments disposals or controls changes of an entity;
  • Any other non-recurring items, such as some costs incurred to realise business combinations and amortisation of an asset exclusively valued in the context of business combination, as well as litigation costs that have arisen outside the ordinary course of business;
  • And including the share in net income of the operational equity-accounted investments.

A non-recurring item is a significant, “one-off” exceptional item that is not expected to occur again in subsequent years.

Adjusted EBIT margin corresponds to Adjusted EBIT expressed as a percentage of sales.

EBITDA before PPA + JV dividends

EBITDA before PPA plus dividends from joint ventures is the EBIT before PPA, before depreciation and amortisation, with the addition of the dividends received from joint ventures.

Adjusted net profit

The “Adjusted Net Profit” KPI restates Alstom’s net profit from continued operations (Group share) to exclude the impact of amortisation of assets exclusively valued when determining the PPA in the context of business combination, net of the corresponding tax effect. This indicator is also aligned with market practice.

Free cash flow

Free Cash Flow is defined as net cash provided by operating activities less capital expenditures including capitalised development costs, net of proceeds from disposals of tangible and intangible assets. Free Cash Flow does not include any proceeds from disposals of activity.

The most directly comparable financial measure to Free Cash Flow calculated and presented in accordance with IFRS is net cash provided by operating activities.

Funds from Operations

Funds from Operations “FFO” in the EBIT before PPA to Free Cash Flow statement refers to the Free Cash Flow generated by Operations, before Working Capital variations.

Contract and Trade Working Capital

Contract Working Capital is the sum of:

  • Contract Assets & Liabilities, which includes the Customer Down-Payments
  • Current provisions, which includes Risks on contracts and Warranties

Trade Working Capital is the Working Capital that is not strictly contractual, hence not included in Project Working Capital. It includes:

  • Inventories
  • Trade Receivables
  • Trade Payables
  • Other elements of Working Capital defined as the sum of Other Current Assets/Liabilities and Non-Current provisions 

Net cash/(debt)

The net cash/(debt) is defined as cash and cash equivalents, marketable securities and other current financial asset, less borrowings.

Organic basis

This press release includes KPIs presented on an actual basis and on an organic basis. Figures given on an organic basis eliminate the impact of changes in scope of consolidation and changes resulting from the translation of the accounts into Euro following the variation of foreign currencies against the Euro.

The Group uses figures prepared on an organic basis both for internal analysis and for external communication, as it believes they provide means to analyse and explain variations from one period to another. However, these figures are not measurements of performance under IFRS.


1 Non-GAAP. See definition in the appendix

2 Non-GAAP. See definition in the appendix

Attachment

East Corner Office Building, Cloche d’Or Luxembourg

East Corner Office Building, Cloche d'Or Luxembourg
East Corner Office Building, Cloche d’Or Luxembourg

PRESS RELEASE

  NON-REGULATED INFORMATION
Luxemburg, November 2, 2026, 7:25 AM

 

Major lease signed at the new ‘East Corner’ office building in Cloche d’Or

Luxemburg, November 2 2026 – Grossfeld, the joint venture between Promobe and Nextensa, announces the arrival of a renowned financial institution at the ‘East Corner’ office building. Strategically located at the entrance to Cloche d’Or, the building stands out for its elegant, contemporary architecture and is scheduled for completion by the end of March 2028. With the arrival of this new financial player, Cloche d’Or further consolidates its position as a key financial hub, thereby strengthening Luxembourg’s Central Business District (CBD).

A renowned financial institution

The new tenant will occupy four floors at East Corner, covering a total area of 4,260 m², at a rent of €46.50 per m² per month under a firm nine-year lease agreement. Like State Street, Lombard Odier, Citi and other renowned financial institutions, the new tenant has chosen a district that is emerging as Luxembourg’s new financial hub. These major institutions place great importance on their employees’ quality of life and well-being, choosing Cloche d’Or for the many advantages the district offers its occupiers.

East Corner: a benchmark in sustainable architectural excellence
Designed by architectural firm 3XN, East Corner stands out for its contemporary architecture, characterised by staggered building volumes, varying heights and recessed façade elements. The building’s location and design complement the district’s landscaping, ensuring harmonious integration into its urban surroundings.
With approximately 7,750 m² of above-ground floor space and 1,900 m² of below-ground space, the building will offer flexible office accommodation designed to meet the evolving needs of its occupiers. Sustainability and occupant well-being are central to its design, with the project targeting BREEAM Outstanding, WELL Core Gold and LBCI certifications.

Cloche d’Or: a strategically located district
Cloche d’Or offers an attractive living and working environment for businesses and residents alike. The district has been developed in line with the principles of New Urban Living, an integrated approach to urban development that combines energy efficiency, mixed-use development and quality of life.
The district holds DGNB Platinum certification, one of Europe’s most demanding standards for sustainable urban development. A large urban park, an ecological corridor connecting the surrounding natural areas and a well-integrated network of pedestrian and cycling routes make Cloche d’Or an attractive, accessible and environmentally friendly district.

For more information:

Nextensa
Nextensa is an investor and developer, renowned for large-scale projects such as the Tour & Taxis site and Bel Towers in Brussels. Specialising in urban expansion and regeneration, Nextensa transforms spaces into vibrant and innovative neighbourhoods. As part of the Ackermans & van Haaren holding company (Euronext), it combines technical expertise with strategic vision to actively contribute to sustainable urban development.

Promobe
A Luxembourg-based property developer for over 40 years, Promobe stands out for its unwavering commitment to quality of life. Specialising in the development of office, retail and residential properties, Promobe creates contemporary, functional and exceptional urban environments. A key player in the development of the Cloche d’Or district, one of the most dynamic and sought-after urban hubs in the Grand Duchy, Promobe has established itself as a leading developer in Luxembourg, delivering projects where elegance, innovation and quality of life come together.

Grossfeld

Grossfeld, a joint venture between Promobe and Nextensa, is the leading player in the development of the mixed-use Cloche d’Or district. For over 20 years, Grossfeld has been shaping this ambitious project, transforming the Cloche d’Or into a true urban hub combining housing, offices, shops, restaurants and green spaces. This neighbourhood has been designed to offer an optimal quality of life, with modern infrastructure, excellent transport links and immediate proximity to all essential services. The Cloche d’Or thus embodies a new way of experiencing the city, where comfort, convenience and economic vitality come together.

NEXTENSA
Michel Van Geyte – Chief Executive Officer
+32 2 882 10 08 – michel.van.geyte@nextensa.eu

PROMOBE
Anne Clarenne – Group Marketing & Communications Officer
+352 367381-1 – anne.clarenne@promobe.lu

GROSSFELD (Promobe & Nextensa joint venture)
Patrick Labey – Manager
+352 248393-1 –patrick.labey@grossfeld.lu

Attachments

East Corner Office Building, Cloche d’Or Luxembourg

East Corner Office Building, Cloche d'Or Luxembourg
East Corner Office Building, Cloche d’Or Luxembourg

PRESS RELEASE

  NON-REGULATED INFORMATION
Luxemburg, November 2, 2026, 7:25 AM

 

Major lease signed at the new ‘East Corner’ office building in Cloche d’Or

Luxemburg, November 2 2026 – Grossfeld, the joint venture between Promobe and Nextensa, announces the arrival of a renowned financial institution at the ‘East Corner’ office building. Strategically located at the entrance to Cloche d’Or, the building stands out for its elegant, contemporary architecture and is scheduled for completion by the end of March 2028. With the arrival of this new financial player, Cloche d’Or further consolidates its position as a key financial hub, thereby strengthening Luxembourg’s Central Business District (CBD).

A renowned financial institution

The new tenant will occupy four floors at East Corner, covering a total area of 4,260 m², at a rent of €46.50 per m² per month under a firm nine-year lease agreement. Like State Street, Lombard Odier, Citi and other renowned financial institutions, the new tenant has chosen a district that is emerging as Luxembourg’s new financial hub. These major institutions place great importance on their employees’ quality of life and well-being, choosing Cloche d’Or for the many advantages the district offers its occupiers.

East Corner: a benchmark in sustainable architectural excellence
Designed by architectural firm 3XN, East Corner stands out for its contemporary architecture, characterised by staggered building volumes, varying heights and recessed façade elements. The building’s location and design complement the district’s landscaping, ensuring harmonious integration into its urban surroundings.
With approximately 7,750 m² of above-ground floor space and 1,900 m² of below-ground space, the building will offer flexible office accommodation designed to meet the evolving needs of its occupiers. Sustainability and occupant well-being are central to its design, with the project targeting BREEAM Outstanding, WELL Core Gold and LBCI certifications.

Cloche d’Or: a strategically located district
Cloche d’Or offers an attractive living and working environment for businesses and residents alike. The district has been developed in line with the principles of New Urban Living, an integrated approach to urban development that combines energy efficiency, mixed-use development and quality of life.
The district holds DGNB Platinum certification, one of Europe’s most demanding standards for sustainable urban development. A large urban park, an ecological corridor connecting the surrounding natural areas and a well-integrated network of pedestrian and cycling routes make Cloche d’Or an attractive, accessible and environmentally friendly district.

For more information:

Nextensa
Nextensa is an investor and developer, renowned for large-scale projects such as the Tour & Taxis site and Bel Towers in Brussels. Specialising in urban expansion and regeneration, Nextensa transforms spaces into vibrant and innovative neighbourhoods. As part of the Ackermans & van Haaren holding company (Euronext), it combines technical expertise with strategic vision to actively contribute to sustainable urban development.

Promobe
A Luxembourg-based property developer for over 40 years, Promobe stands out for its unwavering commitment to quality of life. Specialising in the development of office, retail and residential properties, Promobe creates contemporary, functional and exceptional urban environments. A key player in the development of the Cloche d’Or district, one of the most dynamic and sought-after urban hubs in the Grand Duchy, Promobe has established itself as a leading developer in Luxembourg, delivering projects where elegance, innovation and quality of life come together.

Grossfeld

Grossfeld, a joint venture between Promobe and Nextensa, is the leading player in the development of the mixed-use Cloche d’Or district. For over 20 years, Grossfeld has been shaping this ambitious project, transforming the Cloche d’Or into a true urban hub combining housing, offices, shops, restaurants and green spaces. This neighbourhood has been designed to offer an optimal quality of life, with modern infrastructure, excellent transport links and immediate proximity to all essential services. The Cloche d’Or thus embodies a new way of experiencing the city, where comfort, convenience and economic vitality come together.

NEXTENSA
Michel Van Geyte – Chief Executive Officer
+32 2 882 10 08 – michel.van.geyte@nextensa.eu

PROMOBE
Anne Clarenne – Group Marketing & Communications Officer
+352 367381-1 – anne.clarenne@promobe.lu

GROSSFELD (Promobe & Nextensa joint venture)
Patrick Labey – Manager
+352 248393-1 –patrick.labey@grossfeld.lu

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.